COVID-19肺炎的肺部超声表现及其预后价值
本研究对武汉ICU的48例COVID-19患者行12区法肺部超声检查,分析肺部超声评分与PaO2/FiO2、APACHE II、SOFA、PaCO2及28天死亡率的关系。结果显示肺部超声评分与PaO2/FiO2负相关(r=-0.498,P<0.05),与APACHE II正相关(r=0.435,P<0.05),且是28天死亡率的独立相关因素,ROC曲线下面积0.735(95%CI:0.586-0.844),截断值22.5时敏感性0.833、特异性0.722。肺部超声可用于评估COVID-19肺炎严重程度并显示病理征象。
要点
- ICU入院时肺部超声评分是COVID-19患者28天死亡率的独立相关因素,ROC曲线下面积0.735(95%CI:0.586-0.844)。
- 评分截断值22.5时预测28天死亡的敏感性0.833、特异性0.722,可作为床旁风险分层参考。
- 肺部超声评分与PaO2/FiO2负相关(r=-0.498,P<0.05),与APACHE II正相关(r=0.435,P<0.05)。
- 12区法扫描中,25.9%区域见B7线、23.5%见B3线,13%见融合B线,24.9%见实变,9.9%见A线,2.8%见胸腔积液。
- 肺部超声可显示COVID-19肺炎的病理征象(B线、融合B线、实变、胸腔积液等),用于评估严重程度。
适用人群与场景
- ICU收治的COVID-19肺炎患者(武汉,n=48),于ICU入院时行肺部超声检查。
诊断标准与关键阈值
- 采用12区法肺部超声扫描,计算肺部超声评分。
- 肺部超声评分预测28天死亡的截断值为22.5,敏感性0.833、特异性0.722。
- 肺部超声征象包括B7线、B3线、融合B线(B-pattern)、实变、A线、胸腔积液。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:单中心前瞻性观察性研究(据摘要推断),样本量48例,单中心(武汉),ICU人群。
- 干预:12区法肺部超声检查,计算肺部超声评分;对照:无。
- 主要终点:肺部超声评分与28天死亡率独立相关;ROC曲线下面积0.735(95%CI:0.586-0.844)。
- 关键次要终点:肺部超声评分与PaO2/FiO2负相关(r=-0.498,P<0.05),与APACHE II正相关(r=0.435,P<0.05)。
- 肺部超声征象分布:25.9%区域B7线、23.5%区域B3线、13%区域融合B线、24.9%区域实变、9.9%区域A线、2.8%区域胸腔积液。
证据类型、等级与局限
- 证据类型:单中心观察性研究(摘要未明确标注设计类型),样本量48例。
- 局限:单中心、样本量小;原文未报告证据等级或推荐强度。
对床旁实践的改变
- 对ICU收治的COVID-19肺炎患者,入院时可考虑行12区法肺部超声评分,用于评估病情严重程度和28天死亡风险。
- 肺部超声评分22.5可作为预后判断参考界值,但需结合临床综合判断,不宜单独作为决策依据。
- 肺部超声可显示B线、融合B线、实变、胸腔积液等征象,有助于床旁快速评估肺部病变。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: We used lung ultrasonography to identify features of COVID-19 pneumonia and to evaluate the prognostic value.
PATIENTS AND METHODS: We performed lung ultrasonography on 48 COVID-19 patients in an intensive care unit (ICU) (Wuhan, China) using a 12-zone method. The associations between lung ultrasonography score, PaO2/FiO2, APACHE II, SOFA, and PaCO2 with 28-day mortality were analyzed and the receiver operator characteristic curve was plotted.
RESULTS: 25.9% areas in all scanning zones presented with B7 lines and 23.5% with B3 lines (B-pattern) on lung ultrasonography; 13% areas with confluent B lines (B-pattern), 24.9% in areas with consolidations, and 9.9% in areas with A lines. Pleural effusion was observed in 2.8% of areas. Lung ultrasonography score was negatively correlated with PaO2/FiO2 (n = 48, r = -0.498, P < 0.05) and positively correlated with APACHE II (n = 48, r = 0.435, P < 0.05). Lung ultrasonography score was independently associated with 28-day mortality. The areas under receiver operator characteristic curves of lung ultrasonography score were 0.735 (95% CI: 0.586-0.844). The sensitivity, specificity, and cutoff values were 0.833, 0.722, and 22.5, respectively.
CONCLUSIONS: Lung ultrasonography could be used to assess the severity of COVID-19 pneumonia, and it could also reveal the pathological signs of the disease. The lung ultrasonography score on ICU admission was independently related to the ICU 28-day mortality.
参考来源
- Li L, Qin A, Yang X, et al. Findings and Prognostic Value of Lung Ultrasonography in Coronal Virus Disease 2019 (COVID-19) Pneumonia. Shock. 2021. PMID: 33234837. doi:10.1097/SHK.0000000000001700
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。